Salim Syed
Stock Analyst at Mizuho
(2.96)
# 1,301
Out of 4,496 analysts
58
Total ratings
37.74%
Success rate
2.52%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Reiterates: Outperform | $19 | $5.84 | +225.34% | 4 | Jun 25, 2024 | |
| AMGN Amgen | Maintains: Neutral | $223 → $235 | $331.29 | -29.07% | 5 | May 9, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $22.01 | +54.48% | 1 | Apr 9, 2024 | |
| NKTX Nkarta | Maintains: Buy | $31 → $25 | $6.21 | +302.58% | 6 | Mar 22, 2024 | |
| PCVX Vaxcyte | Maintains: Buy | $69 → $113 | $81.63 | +38.43% | 2 | Mar 12, 2024 | |
| CYTK Cytokinetics | Maintains: Buy | $103 → $99 | $56.41 | +75.50% | 4 | Mar 6, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $54.56 | +81.45% | 3 | Mar 6, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $53 | $26.19 | +102.37% | 7 | Mar 5, 2024 | |
| GILD Gilead Sciences | Maintains: Buy | $101 → $90 | $72.56 | +24.04% | 4 | Feb 22, 2024 | |
| BIIB Biogen | Maintains: Buy | $355 → $277 | $226.40 | +22.35% | 11 | Feb 22, 2024 | |
| ATRA Atara Biotherapeutics | Downgrades: Neutral | $775 → $25 | $11.01 | +127.07% | 3 | Nov 9, 2023 | |
| UBX Unity Biotechnology | Maintains: Buy | $12 → $6 | $1.45 | +313.79% | 4 | Mar 28, 2023 | |
| CHRS Coherus BioSciences | Maintains: Buy | $28 → $21 | $1.64 | +1,180.49% | 3 | Nov 16, 2022 | |
| ASMB Assembly Biosciences | Maintains: Buy | $168 → $36 | $15.13 | +137.94% | 1 | Nov 16, 2022 |
Wave Life Sciences
Jun 25, 2024
Reiterates: Outperform
Price Target: $19
Current: $5.84
Upside: +225.34%
Amgen
May 9, 2024
Maintains: Neutral
Price Target: $223 → $235
Current: $331.29
Upside: -29.07%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $22.01
Upside: +54.48%
Nkarta
Mar 22, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $6.21
Upside: +302.58%
Vaxcyte
Mar 12, 2024
Maintains: Buy
Price Target: $69 → $113
Current: $81.63
Upside: +38.43%
Cytokinetics
Mar 6, 2024
Maintains: Buy
Price Target: $103 → $99
Current: $56.41
Upside: +75.50%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $54.56
Upside: +81.45%
BridgeBio Pharma
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $26.19
Upside: +102.37%
Gilead Sciences
Feb 22, 2024
Maintains: Buy
Price Target: $101 → $90
Current: $72.56
Upside: +24.04%
Biogen
Feb 22, 2024
Maintains: Buy
Price Target: $355 → $277
Current: $226.40
Upside: +22.35%
Atara Biotherapeutics
Nov 9, 2023
Downgrades: Neutral
Price Target: $775 → $25
Current: $11.01
Upside: +127.07%
Unity Biotechnology
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $1.45
Upside: +313.79%
Coherus BioSciences
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.64
Upside: +1,180.49%
Assembly Biosciences
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $15.13
Upside: +137.94%